Clinical Trial Update: Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating safety and efficacy of encorafenib with or without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Jason J. Luke, MD | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-05-23